Comparison · NCT04455815-sae
Camostat vs Control Arm: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Camostat vs Control Arm: serious adverse events. Trial comparisons, record NCT04455815-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04455815-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.25 | 0.102 | 0.495 | wilson | |
| Risk in group 2 | 0.0556 | 0.00988 | 0.258 | wilson | |
| Risk difference, group 1 minus group 2 | 0.194 | -0.0561 | 0.444 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 4.5 | 0.559 | 36.2 | log | |
| Odds ratio, group 1 over group 2 | 5.67 | 0.561 | 57.2 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Camostat than on Control Arm | 5.14 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: control.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Camostat | Patient to receive treatment with camostat tablets, 200mg four times daily (qds) for 14 days.~Camostat: Patient to receive treatment with camostat tablets, 200mg four times daily (qds) for 14 days. | 4 | 16 | EG000 |
| Group 2 | Control Arm | Patient to receive best supportive care. | 1 | 18 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Safety data was collected from the time of informed consent until 28 days from Day 1.Patients who were hospitalised were followed up for up to 28 days after they were discharged.
Source ClinicalTrials.gov
Trial
- Title
- A Trial Looking at the Use of Camostat in People Who Have Tested Positive for Coronavirus (COVID-19) (SPIKE-1)
- NCT number
- NCT04455815
- Phases
- PHASE2
- Conditions
- COVID-19 Infection
- Interventions
- Camostat
- Lead sponsor
- Cancer Research UK
- Results first posted
- 2023-12-11
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04455815?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04455815-sae